The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer
Cancer Biotherapy and Radiopharmaceuticals · 2024
DOI: 10.1089/cbr.2024.0011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Ruoyang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Doxorubicin, Breast Neoplasms, Polyethylene Glycols, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Medicine, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
ORCID-Profile: Zhenchuan Song
Zitieren
APA
Li, R., Zhao, X., Huang, Y., Li, C., Liu, L., Wang, M., Wang, J., & Song, Z. (2024). The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2024.0011
Vancouver
Li R, Zhao X, Huang Y, Li C, Liu L, Wang M, et al. The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2024.0011
BibTeX
@article{Li2024,
author = {Li, Ruoyang and Zhao, Xuewei and Huang, Yunfei and Li, Chunxiao and Liu, Lei and Wang, Meiqi and Wang, Jiaxing and Song, Zhenchuan},
title = {The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2024},
doi = {10.1089/cbr.2024.0011}
}
EUVIMED